Ultrasound may spot breast cancer response weeks early
NCT ID NCT05957042
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study aimed to see if contrast-enhanced ultrasound (CEUS) could predict whether triple negative breast cancer patients are responding to chemotherapy and immunotherapy earlier than standard MRI or CT scans. The study was withdrawn before enrolling any participants, so no results are available. It was planned as a small pilot study to gather initial data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Penn State Health College of Medicine
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.